Relationship Between Serum Myostatin Level and Cardiovascular Calcifications in Chronic Kidney Disease Patients

Authors

Ahmed Alaa-Eldin Ahmed Saad, Internal Medicine and Nephrology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt
Alsayed Mohamed Rashed, Internal Medicine and Nephrology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt
Mohamed Abol Wafa Amin Ahmed, Diagnostic Radiology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt
Mohamed Elsayed Abo Ghabsha, Clinical Pathology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt
Mohamed Zaher Mohamed Abd Elhakim, Internal Medicine and Nephrology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, EgyptFollow

Corresponding Author

Mohamed Zaher Mohamed Abd Elhakim

Abstract

Background: With its detrimental effects, including kidney failure, cardiovascular disease, and early mortality, chronic kidney disease(CKD) is a global public health concern.

Aim and objectives: To evaluate serum myostatin levels and their association with cardiovascular calcifications in patients with chronic kidney disease.

Patients and methods: A case-control study was conducted on 90 participants, and they were divided into three groups: Group A included 30 patients with chronic kidney disease; Group B include30 patients diagnosed with end-stage kidney disease on regular hemodialysis; and the control group included 30 apparently healthy individuals as a control group. Ages and sex were matched with the above groups. The patients were collected from the Nephrology Units, Department of Internal Medicine, Syed Galal University Hospital, Cairo, Egypt, from May 2023 to December 2023.

Results: The results provide compelling evidence that myostatin plays a significant role in the pathophysiology of cardiovascular complications in CKD and ESRD patients.

Conclusion: Serum myostatin was higher in CKD&ESKD patients than in the control group. A positive correlation between serum myostatin levels and cardiovascular calcifications suggests that myostatin could serve as a valuable biomarker for identifying CKD&ESKD patients at high risk for cardiovascular events. Monitoring myostatin levels might help in early detection and intervention, potentially improving cardiovascular outcomes in this population. Additionally, therapeutic strategies targeting myostatin pathways could be developed to mitigate cardiovascular complications in CKD patients.

Authors ORCID

https://orcid.org/0009-0009-8592-7019

Article Type

Original Article

Keywords

Serum myostatin level; Cardiovascular calcifications; CKD

Subject Area

Internal Medicine

How to Cite This Article

Saad, Ahmed Alaa-Eldin Ahmed; Rashed, Alsayed Mohamed; Ahmed, Mohamed Abol Wafa Amin; Abo Ghabsha, Mohamed Elsayed; and Abd Elhakim, Mohamed Zaher Mohamed (2024) "Relationship Between Serum Myostatin Level and Cardiovascular Calcifications in Chronic Kidney Disease Patients," Al-Azhar International Medical Journal: Vol. 5: Iss. 12, Article 27.
DOI: https://doi.org/10.58675/2682-339X.2806